JP2002542196A - 細胞容量調節ヒトキナーゼｈ−ｓｇｋのインヒビター含有医薬 - Google Patents
細胞容量調節ヒトキナーゼｈ−ｓｇｋのインヒビター含有医薬Info
- Publication number
- JP2002542196A JP2002542196A JP2000611917A JP2000611917A JP2002542196A JP 2002542196 A JP2002542196 A JP 2002542196A JP 2000611917 A JP2000611917 A JP 2000611917A JP 2000611917 A JP2000611917 A JP 2000611917A JP 2002542196 A JP2002542196 A JP 2002542196A
- Authority
- JP
- Japan
- Prior art keywords
- sgk
- expression
- kinase
- cell volume
- volume regulating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091000080 Phosphotransferase Proteins 0.000 title claims abstract description 28
- 102000020233 phosphotransferase Human genes 0.000 title claims abstract description 28
- 239000003112 inhibitor Substances 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 8
- 229940079593 drug Drugs 0.000 title claims description 3
- 239000012190 activator Substances 0.000 claims abstract description 11
- LLEJIEBFSOEYIV-UHFFFAOYSA-N chelerythrine Chemical compound C1=C2OCOC2=CC2=CC=C3C4=CC=C(OC)C(OC)=C4C=[N+](C)C3=C21 LLEJIEBFSOEYIV-UHFFFAOYSA-N 0.000 claims description 18
- RATMHCJTVBHJSU-UHFFFAOYSA-N Dihydrochelerythrine Natural products C1=C2OCOC2=CC2=C(N(C)C(O)C=3C4=CC=C(C=3OC)OC)C4=CC=C21 RATMHCJTVBHJSU-UHFFFAOYSA-N 0.000 claims description 9
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 claims description 9
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 claims description 9
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 claims description 9
- 230000003352 fibrogenic effect Effects 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 206010033645 Pancreatitis Diseases 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 6
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 5
- 206010006451 bronchitis Diseases 0.000 claims description 5
- 208000007451 chronic bronchitis Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 230000008499 blood brain barrier function Effects 0.000 claims description 4
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 208000007530 Essential hypertension Diseases 0.000 claims description 2
- 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 claims 1
- 206010067953 Radiation fibrosis Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 230000014509 gene expression Effects 0.000 abstract description 26
- 230000003247 decreasing effect Effects 0.000 abstract description 2
- 239000011734 sodium Substances 0.000 description 18
- 101000640897 Squalus acanthias Solute carrier family 12 member 2 Proteins 0.000 description 17
- 230000000638 stimulation Effects 0.000 description 14
- 102000009618 Transforming Growth Factors Human genes 0.000 description 13
- 108010009583 Transforming Growth Factors Proteins 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 230000004186 co-expression Effects 0.000 description 11
- 210000000287 oocyte Anatomy 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 9
- 102100022094 Acid-sensing ion channel 2 Human genes 0.000 description 8
- 101710099902 Acid-sensing ion channel 2 Proteins 0.000 description 8
- 102000004954 Biglycan Human genes 0.000 description 8
- 108090001138 Biglycan Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229960003883 furosemide Drugs 0.000 description 8
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 8
- 229940043355 kinase inhibitor Drugs 0.000 description 8
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000004941 influx Effects 0.000 description 5
- 108091006146 Channels Proteins 0.000 description 4
- 108020003264 Cotransporters Proteins 0.000 description 4
- 102000034534 Cotransporters Human genes 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 108060003393 Granulin Proteins 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000008587 neuronal excitability Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 108020004518 RNA Probes Proteins 0.000 description 2
- 239000003391 RNA probe Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- CWUAAQVTCQLNTH-UHFFFAOYSA-N 1-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OS(=O)(=O)C(C)N1CCN(CCO)CC1 CWUAAQVTCQLNTH-UHFFFAOYSA-N 0.000 description 1
- DGOSGFYDFDYMCW-OEFRVDPMSA-N 4alpha-phorbol 12,13-didecanoate Chemical compound C([C@@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(=O)CCCCCCCCC)C1(C)C DGOSGFYDFDYMCW-OEFRVDPMSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108010033806 Degenerin Sodium Channels Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000030632 cutaneous sclerosis Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000000277 pancreatic duct Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000033990 renal sodium ion absorption Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19917990A DE19917990A1 (de) | 1999-04-20 | 1999-04-20 | Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk |
| DE19917990.5 | 1999-04-20 | ||
| PCT/EP2000/003578 WO2000062781A1 (de) | 1999-04-20 | 2000-04-19 | Arzneimittel enthaltend hemmstoffe der zellvolumenregulierten humanen kinase h-sgk |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002542196A true JP2002542196A (ja) | 2002-12-10 |
| JP2002542196A5 JP2002542196A5 (es) | 2007-06-14 |
Family
ID=7905297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000611917A Pending JP2002542196A (ja) | 1999-04-20 | 2000-04-19 | 細胞容量調節ヒトキナーゼｈ−ｓｇｋのインヒビター含有医薬 |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1171131A1 (es) |
| JP (1) | JP2002542196A (es) |
| KR (1) | KR100718900B1 (es) |
| CN (1) | CN1351496A (es) |
| AU (1) | AU779941B2 (es) |
| BR (1) | BR0009914A (es) |
| CA (1) | CA2369078A1 (es) |
| CZ (1) | CZ20013778A3 (es) |
| DE (1) | DE19917990A1 (es) |
| HU (1) | HUP0200819A3 (es) |
| MX (1) | MXPA01010588A (es) |
| NO (1) | NO20015054L (es) |
| PL (1) | PL198427B1 (es) |
| RU (1) | RU2288718C9 (es) |
| SK (1) | SK14972001A3 (es) |
| UA (1) | UA79066C2 (es) |
| WO (1) | WO2000062781A1 (es) |
| ZA (1) | ZA200108610B (es) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005082402A1 (ja) * | 2004-03-02 | 2005-09-09 | Hokkaido Technology Licensing Office Co., Ltd. | 臓器線維症予防・治療剤 |
| JP2007527875A (ja) * | 2004-03-11 | 2007-10-04 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 線維症を抑制するための方法 |
| JP2007529423A (ja) * | 2004-03-11 | 2007-10-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 血清・グルココルチコイド誘導性キナーゼのモジュレータの使用を含む、神経精神疾患を治療するためのグルタミン酸受容体の調節方法 |
| JP2008504241A (ja) * | 2004-06-26 | 2008-02-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | オルト置換ｎ’−ベンジリデン−（３−ヒドロキシフェニル）アセトヒドラジド類 |
| JP2008535833A (ja) * | 2005-04-04 | 2008-09-04 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 特にｓｇｋについてのキナーゼ阻害剤としてのアシルヒドラジド類 |
| JP4762552B2 (ja) * | 2003-03-03 | 2011-08-31 | フロリアン ラング、 | 診断用および治療用標的としてのｓｇｋ１ |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10042137A1 (de) * | 2000-08-28 | 2002-03-14 | Florian Lang | sgk2 und sgk3 als diagnostische und therapeutische Targets |
| DE10113876A1 (de) * | 2001-03-21 | 2002-09-26 | Eberhard Karls Uni Medizinisch | Quantitative diagnostische Analyse der Hypertonie |
| CA2449794A1 (en) | 2001-04-27 | 2002-11-07 | Cold Spring Harbor Laboratory | Alleviation of the memory deficits and memory components of psychiatric dysfunctions by altering atypical pkm activity |
| DE10149393A1 (de) * | 2001-09-28 | 2003-04-24 | Florian Lang | sgk1 als diagnostisches und therapeutisches target |
| DE10225844A1 (de) * | 2002-06-04 | 2003-12-18 | Lang Florian | sgk und nedd als diagnostische und therapeutische targets |
| DE10305212A1 (de) * | 2003-02-07 | 2004-08-19 | Florian Prof. Dr.med. Lang | Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom |
| WO2004084889A1 (en) * | 2003-03-28 | 2004-10-07 | Pfizer Inc. | Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons |
| DE10346913A1 (de) * | 2003-10-09 | 2005-05-04 | Merck Patent Gmbh | Acylhydrazonderivate |
| US20090136920A1 (en) * | 2004-04-30 | 2009-05-28 | Stefan Golz | Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1) |
| WO2005118832A2 (en) * | 2004-06-01 | 2005-12-15 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase-like protein (sgkl) |
| MX2007001155A (es) * | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
| DE102005001053A1 (de) * | 2005-01-07 | 2006-07-20 | Merck Patent Gmbh | Quadratsäurederivate |
| DE102005035742A1 (de) * | 2005-07-29 | 2007-02-01 | Merck Patent Gmbh | Quadratsäurederivate II |
| DE102005039541A1 (de) * | 2005-08-22 | 2007-03-22 | Merck Patent Gmbh | 3-Oxo-indazol-quadratsäurederivate |
| DE102007002717A1 (de) | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
| DE102007022565A1 (de) | 2007-05-14 | 2008-11-20 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
| EP2014651A1 (en) * | 2007-07-12 | 2009-01-14 | Exonhit Therapeutics SA | Compounds and methods for modulating Rho GTPases |
| DE102008010363A1 (de) | 2008-02-18 | 2009-08-20 | Lang, Florian, Prof. Dr.med. | Sgk1 als therapeutisches und diagnostisches Target für karzinomatöse Erkrankungen |
| DE102008010362A1 (de) | 2008-02-18 | 2009-08-20 | Florian Prof. Dr. Lang | Sgk1 als therapeutisches und diagnostisches Target für virale Erkrankungen |
| DE102008010361A1 (de) | 2008-02-18 | 2009-08-20 | Merck Patent Gmbh | sgk1-Inhibitoren zur Prophylaxe und/oder Therapie von viralen Erkrankungen und/oder Karzinomen |
| DE102008029072A1 (de) * | 2008-06-10 | 2009-12-17 | Lang, Florian, Prof. Dr.med. | Sgk3 als therapeutisches und diagnostisches Target für Alterserkrankungen |
| DE102008038222A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | Indazol-5-carbonsäurehydrazid-derivate |
| DE102008038220A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | Oxadiazolderivate |
| DE102008038221A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | 7-Azaindolderivate |
| DE102008059133A1 (de) | 2008-11-26 | 2010-05-27 | Merck Patent Gmbh | Difluorphenyl-diacylhydrazid-derivate |
| WO2012064981A2 (en) * | 2010-11-10 | 2012-05-18 | National Jewish Health | Methods to test allergic conditions |
| CN107875153A (zh) * | 2017-11-16 | 2018-04-06 | 上海壹志医药科技有限公司 | 去甲白屈菜红碱的药物用途 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5373501A (en) * | 1976-12-11 | 1978-06-30 | Kitasato Inst | Novel antibiotics amm2282 and process for preparing same |
| JPH1192401A (ja) * | 1997-06-27 | 1999-04-06 | Smithkline Beecham Corp | ヒト血清グルココルチコイドにより調節されるキナーゼ、慢性腎不全に対する標的 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5242397A (en) * | 1989-06-20 | 1993-09-07 | Cedars-Sinai Medical Center | Catheter device and method of use for intramural delivery of protein kinase C and tyrosine protein kinase inhibitors to prevent restenosis after balloon angioplasty |
| US5137912A (en) * | 1991-01-28 | 1992-08-11 | National Science Council Of Republic Of China | Chelerythrine inhibits platelet aggregation--a potential anti-aggregation drug |
| GB9325395D0 (en) * | 1993-12-11 | 1994-02-16 | Ciba Geigy Ag | Compositions |
| US5874464A (en) * | 1995-01-13 | 1999-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Conformationally constrained diacylglycerol analogues |
| AU6888196A (en) * | 1995-08-11 | 1997-03-12 | Yale University | Glycosylated indolocarbazole synthesis |
| PT906268E (pt) * | 1996-05-30 | 2002-05-31 | Aventis Pharma Inc | Fluorenonas com substituicao alquiloxiamino e sua utilizacao como inibidores da proteina quinase c |
| EP0889127A1 (en) * | 1997-07-01 | 1999-01-07 | Smithkline Beecham Corporation | Serine/threonine protein kinase (H-SGK2) |
| CO4940430A1 (es) * | 1997-07-07 | 2000-07-24 | Novartis Ag | Compuestos policiclicos que contienen estaurosporina hidrogenada con propiedades farmacologicas convenientes y un efecto inhibidor sobre el crecimiento de las celulas tumorales |
-
1999
- 1999-04-20 DE DE19917990A patent/DE19917990A1/de not_active Ceased
-
2000
- 2000-04-19 JP JP2000611917A patent/JP2002542196A/ja active Pending
- 2000-04-19 CZ CZ20013778A patent/CZ20013778A3/cs unknown
- 2000-04-19 PL PL352547A patent/PL198427B1/pl unknown
- 2000-04-19 WO PCT/EP2000/003578 patent/WO2000062781A1/de not_active Application Discontinuation
- 2000-04-19 CN CN00807959A patent/CN1351496A/zh active Pending
- 2000-04-19 HU HU0200819A patent/HUP0200819A3/hu unknown
- 2000-04-19 KR KR1020017013336A patent/KR100718900B1/ko not_active IP Right Cessation
- 2000-04-19 UA UA2001117896A patent/UA79066C2/uk unknown
- 2000-04-19 MX MXPA01010588A patent/MXPA01010588A/es not_active Application Discontinuation
- 2000-04-19 AU AU42972/00A patent/AU779941B2/en not_active Ceased
- 2000-04-19 SK SK1497-2001A patent/SK14972001A3/sk unknown
- 2000-04-19 RU RU2001131351/15A patent/RU2288718C9/ru not_active IP Right Cessation
- 2000-04-19 BR BR0009914-7A patent/BR0009914A/pt not_active Application Discontinuation
- 2000-04-19 CA CA002369078A patent/CA2369078A1/en not_active Abandoned
- 2000-04-19 EP EP00922655A patent/EP1171131A1/de not_active Withdrawn
-
2001
- 2001-10-17 NO NO20015054A patent/NO20015054L/no not_active Application Discontinuation
- 2001-10-19 ZA ZA200108610A patent/ZA200108610B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5373501A (en) * | 1976-12-11 | 1978-06-30 | Kitasato Inst | Novel antibiotics amm2282 and process for preparing same |
| JPH1192401A (ja) * | 1997-06-27 | 1999-04-06 | Smithkline Beecham Corp | ヒト血清グルココルチコイドにより調節されるキナーゼ、慢性腎不全に対する標的 |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4762552B2 (ja) * | 2003-03-03 | 2011-08-31 | フロリアン ラング、 | 診断用および治療用標的としてのｓｇｋ１ |
| WO2005082402A1 (ja) * | 2004-03-02 | 2005-09-09 | Hokkaido Technology Licensing Office Co., Ltd. | 臓器線維症予防・治療剤 |
| JP2007527875A (ja) * | 2004-03-11 | 2007-10-04 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 線維症を抑制するための方法 |
| JP2007529423A (ja) * | 2004-03-11 | 2007-10-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 血清・グルココルチコイド誘導性キナーゼのモジュレータの使用を含む、神経精神疾患を治療するためのグルタミン酸受容体の調節方法 |
| JP2008504241A (ja) * | 2004-06-26 | 2008-02-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | オルト置換ｎ’−ベンジリデン−（３−ヒドロキシフェニル）アセトヒドラジド類 |
| JP2008535833A (ja) * | 2005-04-04 | 2008-09-04 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 特にｓｇｋについてのキナーゼ阻害剤としてのアシルヒドラジド類 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000062781A1 (de) | 2000-10-26 |
| HUP0200819A3 (en) | 2009-08-28 |
| DE19917990A1 (de) | 2000-11-02 |
| PL198427B1 (pl) | 2008-06-30 |
| UA79066C2 (en) | 2007-05-25 |
| PL352547A1 (en) | 2003-08-25 |
| CN1351496A (zh) | 2002-05-29 |
| NO20015054D0 (no) | 2001-10-17 |
| RU2288718C2 (ru) | 2006-12-10 |
| KR20020012172A (ko) | 2002-02-15 |
| SK14972001A3 (sk) | 2002-06-04 |
| KR100718900B1 (ko) | 2007-05-17 |
| HUP0200819A2 (hu) | 2002-07-29 |
| AU4297200A (en) | 2000-11-02 |
| ZA200108610B (en) | 2002-01-02 |
| NO20015054L (no) | 2001-12-14 |
| CA2369078A1 (en) | 2000-10-26 |
| EP1171131A1 (de) | 2002-01-16 |
| CZ20013778A3 (cs) | 2002-06-12 |
| MXPA01010588A (es) | 2004-09-06 |
| BR0009914A (pt) | 2002-01-08 |
| AU779941B2 (en) | 2005-02-17 |
| RU2288718C9 (ru) | 2008-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002542196A (ja) | 細胞容量調節ヒトキナーゼｈ−ｓｇｋのインヒビター含有医薬 | |
| EP3389725B1 (en) | Compositions and methods for treatment of central nervous system diseases | |
| Xia et al. | Damaged brain accelerates bone healing by releasing small extracellular vesicles that target osteoprogenitors | |
| US6887853B2 (en) | Use of geldanamycin and related compounds for treatment of fibrogenic disorders | |
| US6214569B1 (en) | Methods for screening for inhibitors of Alzheimer β-peptide filament formation | |
| Matsumoto et al. | Two unrelated patients with MRE11A mutations and Nijmegen breakage syndrome-like severe microcephaly | |
| Venkatesh et al. | Differential glucocorticoid regulation of the pulmonary hydrophobic surfactant proteins SP-B and SP-C | |
| Tibshirani et al. | Dysregulation of chromatin remodelling complexes in amyotrophic lateral sclerosis | |
| Isosomppi et al. | Developmental expression of palmitoyl protein thioesterase in normal mice | |
| Watlington et al. | Corticosterone 6 beta-hydroxylation correlates with blood pressure in spontaneously hypertensive rats | |
| Liu et al. | CNC-bZIP protein NFE2L1 regulates osteoclast differentiation in antioxidant-dependent and independent manners | |
| Maione et al. | Ca2+ dysregulation in cardiac stromal cells sustains fibro-adipose remodeling in Arrhythmogenic Cardiomyopathy and can be modulated by flecainide | |
| US20050064501A1 (en) | Medicaments comprising inhibitors of the cell volume-regulated human kinase h-sgk | |
| Suda et al. | Effects of corticotropin-releasing hormone and dexamethasone on proopiomelanocortin messenger RNA level in human corticotroph adenoma cells in vitro. | |
| Nicolas et al. | A postzygotic de novo NCDN mutation identified in a sporadic FTLD patient results in neurochondrin haploinsufficiency and altered FUS granule dynamics | |
| AU2003238462A1 (en) | Sgk and nedd used as diagnostic and therapeutic targets | |
| Tanaka et al. | The transcription factor HNF1α regulates expression of chloride-proton exchanger ClC-5 in the renal proximal tubule | |
| Pácha et al. | Carbenoxolone accelerates maturation of rat intestine | |
| Toutenhoofd et al. | Regulation of calmodulin mRNAs in differentiating human IMR-32 neuroblastoma cells | |
| Verhoeven et al. | Nimesulide inhibits platelet-activating factor synthesis in activated human neutrophils | |
| Maher et al. | Partial cloning of the M subunit of laminin from adult rat lipocytes: expression of the M subunit by cells isolated from normal and injured liver | |
| Sobczak et al. | Specific inhibition of epithelial Na+ channels by antisense oligonucleotides for the treatment of Na+ hyperabsorption in cystic fibrosis | |
| Chen | Role of peripheral CB1 cannabinoid receptors in atherosclerosis and metabolism | |
| US20210236438A1 (en) | Compounds and methods for the treatment of autism spectrum disorder and other neurological or psychiatric disorders | |
| Odelin et al. | Variations in the poly-histidine repeat motif of HOXA1 predispose individuals to bicuspid aortic valve |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070419 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070419 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100720 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110125 |